Navigation Links
PharmAthene to Present at the BIO CEO & Investor Conference 2008
Date:2/6/2008

ANNAPOLIS, Md., Feb. 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and Chief Executive Officer of PharmAthene, will present at the BIO CEO & Investor Conference 2008, in New York, NY on Wednesday, February 13, 2008 at 2:00 p.m. The presentation is scheduled to take place in the Basildon Room at the Waldorf Astoria Hotel.

PharmAthene's presentation will be available via webcast on the company's website at http://www.pharmathene.com. A link to access the webcast will be accessible from both the homepage and the investor relations pages of the PharmAthene corporate website. For assistance, contact Stacey Jurchison at 410-269-2610.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.pharmathene.com.


'/>"/>
SOURCE PharmAthene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has filed its Annual Report on Form ... filed Form 20-F includes audited financial statements for the ... can be accessed by visiting the U.S. Securities and ...
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... BERKELEY HEIGHTS, N.J., June 5 Genta,Incorporated (OTC Bulletin ... into definitive agreements with institutional and accredited,investors to ... in,aggregate up to $40 million in gross proceeds ... $20 million of Notes is expected to take ...
... Life Sciences Inc.,(TSX: PLI) ("ProMetic") announced today that ... earlier this year with the Wuhan,Institute of Biological ... ("CNBG") was held on Wednesday, June 4, 2008 ... were CNBG,s President and Chief Executive,Officer Ms. Lifeng ...
... 2009 and ... ... serve as an ideal launching pad that positions the company for,new ... Monsanto,s executive vice president of global,commercial, will tell investors today at ...
Cached Biology Technology:Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 2Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 3Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 4Official Signing Ceremony for WIBP Strategic Alliance 2Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 2Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 3Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 4
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... that can sail throughout the body via the bloodstream ... and ferry their cargo of anti-cancer drugs and markers ... In a forthcoming issue of the Germany-based chemistry ... Diego, UC Santa Barbara and MIT report that their ...
... this goal, scientists at the OU Cancer Institute have found ... they can target the cells and kill them, keeping cancer ... of Oklahoma led by Courtney Houchen, M.D., and Shrikant Anant, ... cells. Until now, researchers knew of proteins that appeared in ...
... -- What,s the worst that could happen after eating a ... But for up to a million women in the ... have a chronic bladder condition that causes pelvic pain. Spicy ... can cause a flare in their symptoms and intensify the ...
Cached Biology News:Researchers develop nano-sized 'cargo ships' to target and destroy tumors 2Researchers develop nano-sized 'cargo ships' to target and destroy tumors 3Researchers develop nano-sized 'cargo ships' to target and destroy tumors 4The pepperoni pizza hypothesis 2The pepperoni pizza hypothesis 3
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
SHEEP ANTI DEHYDROEPIANDROSTERONE...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Biology Products: